Related Experiment Video
Updated: Nov 11, 2025

Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Associations of Brain Atrophy and Cerebral Iron Accumulation at MRI with Clinical Severity in Wilson Disease
Petr Dusek1, Artem Lescinskij1, Filip Ruzicka1
1From the Department of Radiology (P.D., A.L.), Department of Neurology and Centre of Clinical Neuroscience (P.D., F.R.) and Fourth Department of Internal Medicine (R.B.), First Faculty of Medicine, Charles University and General University Hospital, Katerinska 30, 120 00, Prague 2, Czech Republic; Tenoke, Cambridge, England (J.A.C.); Department of Cybernetics, Faculty of Electrical Engineering, Czech Technical University in Prague, Prague, Czech Republic (T.S.); and Magnetic Resonance Unit, Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (M.H., M.D.).
Abstract:
Background Abnormal findings at brain MRI in patients with neurologic Wilson disease (WD) are characterized by signal intensity changes and cerebral atrophy. T2 signal hypointensities and atrophy are largely irreversible with treatment; their relationship with permanent disability has not been systematically investigated. Purpose To investigate associations of regional brain atrophy and iron accumulation at MRI with clinical severity in participants with neurologic WD who are undergoing long-term anti-copper treatment. Materials and Methods Participants with WD and controls were compared in a prospective study performed from 2015 to 2019. MRI at 3.0 T included three-dimensional T1-weighted and six-echo multigradient-echo pulse sequences for morphometry and quantitative susceptibility mapping, respectively. Neurologic severity was assessed with the Unified WD Rating Scale (UWDRS). Automated multi-atlas segmentation pipeline with dual contrast (susceptibility and T1) was used for the calculation of volumes and mean susceptibilities in deep gray matter nuclei. Additionally, whole-brain analysis using deformation and surface-based morphometry was performed. Least absolute shrinkage and selection operator regression was used to assess the association of regional volumes and susceptibilities with the UWDRS score. Results Twenty-nine participants with WD (mean age, 47 years ± 9 [standard deviation]; 15 women) and 26 controls (mean age, 45 years ± 12; 14 women) were evaluated. Whole-brain analysis demonstrated atrophy of the deep gray matter nuclei, brainstem, internal capsule, motor cortex and corticospinal pathway, and visual cortex and optic radiation in participants with WD (P < .05 at voxel level, corrected for family-wise error). The UWDRS score was negatively correlated with volumes of putamen (r = -0.63, P < .001), red nucleus (r = -0.58, P = .001), globus pallidus (r = -0.53, P = .003), and substantia nigra (r = -0.50, P = .006) but not with susceptibilities. Only the putaminal volume was identified as a stable factor associated with the UWDRS score (R2 = 0.38, P < .001) using least absolute shrinkage and selection operator regression. Conclusion Individuals with Wilson disease (WD) had widespread brain atrophy most pronounced in the central structures. The putaminal volume was associated with the Unified WD Rating Scale score and can be used as a surrogate imaging marker of clinical severity. © RSNA, 2021 Supplemental material is available for this article. See also the editorial by Du and Bydder in this issue.
Insights
Brain atrophy, particularly in the putamen, is linked to disability in Wilson disease (WD) patients. Putaminal volume serves as a reliable imaging marker for assessing neurologic Wilson disease severity.
Area of Science:
- Neurology
- Radiology
- Medical Imaging
Background:
- Neurologic Wilson disease (WD) presents with brain MRI abnormalities including signal intensity changes and atrophy.
- These MRI findings, especially T2 signal hypointensities and atrophy, may be irreversible with treatment.
- The link between these irreversible changes and permanent disability in WD has not been thoroughly studied.
Purpose of the Study:
- To examine the relationship between regional brain atrophy and iron accumulation on MRI.
- To assess the association of these MRI findings with clinical severity in neurologic WD patients undergoing treatment.
- To identify potential imaging biomarkers for neurologic disability in WD.
Main Methods:
- A prospective study compared 29 participants with WD and 26 controls from 2015 to 2019.
- Advanced MRI techniques (3.0 T, 3D T1-weighted, and multi-echo gradient-echo sequences) were used for morphometry and quantitative susceptibility mapping.
- Automated segmentation and regression analyses (LASSO) were employed to correlate regional brain volumes and iron accumulation (susceptibility) with neurologic severity (Unified WD Rating Scale - UWDRS).
Main Results:
- Participants with WD showed significant atrophy in deep gray matter nuclei, brainstem, internal capsule, motor cortex, and visual pathways compared to controls.
- UWDRS scores negatively correlated with the volumes of the putamen, red nucleus, globus pallidus, and substantia nigra.
- Putaminal volume emerged as the most significant and stable imaging predictor of clinical severity (UWDRS score).
Conclusions:
- Wilson disease patients exhibit widespread brain atrophy, predominantly in central brain structures.
- Putaminal volume is a key imaging marker associated with clinical disability in neurologic WD.
- This finding suggests putaminal volume can serve as a surrogate marker for assessing neurologic severity in Wilson disease.

